ArticleAntimicrobial agents and chemotherapy2021
Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants.
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- The global epidemiology and treatment of metallo-β-lactamase-producing gram-negative pathogens.JAC-antimicrobial resistance · 2026Review
- Molecular Characterization and In Silico Functional Insights into Carbapenem Resistance in ClinicalPathogens (Basel, Switzerland) · 2026Article
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- The rise and global spread of IMP carbapenemases (1996-2023): a genomic epidemiology study.Nature communications · 2025Article
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- Inhibitor Affinity Differs among Clinical Variants of IMP Metallo-ACS infectious diseases · 2025Article
- Finding the MissingAntibiotics (Basel, Switzerland) · 2025Article
- The emerging concern of IMP variants being resistant to the only IMP-type metallo-β-lactamase inhibitor, xeruborbactam.Antimicrobial agents and chemotherapy · 2025Article
- The rise and global spread of IMP carbapenemases (1996-2023): a genomic epidemiology study.medRxiv : the preprint server for health sciences · 2025Article
- The impact of zinc supplementation on carbapenem MICs among bacteria expressing IMP metallo-beta-lactamase.Access microbiology · 2025Article
- The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-β-lactamase against tebipenem.Antimicrobial agents and chemotherapy · 2024Article
- Tackling Carbapenem Resistance and the Imperative for One Health Strategies-Insights from the Portuguese Perspective.Antibiotics (Basel, Switzerland) · 2024Review
- Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced inAntimicrobial agents and chemotherapy · 2024Article
- Machine Learning Models Identify Inhibitors of New Delhi Metallo-β-lactamase.Journal of chemical information and modeling · 2024Article
- Colistin Resistance Mediated byInfection and drug resistance · 2024Article
- Resistome and Genome Analysis of an Extensively Drug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Small-molecule inhibitors of bacterial-producing metallo-β-lactamases: insights into their resistance mechanisms and biochemical analyses of their activities.RSC medicinal chemistry · 2023Review
- Structural insights into the design of reversible fluorescent probes for metallo-β-lactamases NDM-1, VIM-2, and IMP-1.Journal of inorganic biochemistry · 2022Article
- Metallo-β-lactamases and a tug-of-war for the available zinc at the host-pathogen interface.Current opinion in chemical biology · 2022Review
- Classification and molecular characteristics ofFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Zishuo ChengDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.ORCID 0000-0001-8512-734X
Christopher R BethelResearch Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Pei W ThomasDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, and the LaMontagne Center for Infectious Disease, University of Texas, Austin, Texas, USA.
Ben A ShurinaDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
John-Paul AlaoDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Caitlyn A ThomasDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Kundi YangDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Steven H MarshallResearch Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Huan ZhangDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Aidan M SturgillDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.
Andrea N KravatsDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA kravatan@miamioh.edu robert.bonomo@va.gov crowdemw@miamioh.edu.
Richard C PageDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA.ORCID 0000-0002-3006-3171
Walter FastDivision of Chemical Biology and Medicinal Chemistry, College of Pharmacy, and the LaMontagne Center for Infectious Disease, University of Texas, Austin, Texas, USA.ORCID 0000-0001-7567-2213
Robert A BonomoResearch Services, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA kravatan@miamioh.edu robert.bonomo@va.gov crowdemw@miamioh.edu.ORCID 0000-0002-3299-894X
Michael W CrowderDepartment of Chemistry and Biochemistry, Miami University, Oxford, Ohio, USA kravatan@miamioh.edu robert.bonomo@va.gov crowdemw@miamioh.edu.ORCID 0000-0002-3138-0283
Miami University · USLouis Stokes Cleveland VA Medical Center · USGeriatric Research Education and Clinical Center · US
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MTriage mechanisms for directing protein refolding and degradationR35GM128595 · NIGMS · MIAMI UNIVERSITY OXFORD · PI Richard C Page · 2018 to 2026
$2.8MDeveloping Metallo-Beta-Lactamase InhibitorsR01GM111926 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI BONOMO, ROBERT A., COHEN, SETH M · 2015 to 2019
$2.3MMachine Learning Approach for finding novel metallo-b-lactamase inhibitorsR15GM134454 · NIGMS · MIAMI UNIVERSITY OXFORD · PI CROWDER, MICHAEL W · 2019 to 2022
$867kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIGMS NIH HHS R01 GM111926NIGMS NIH HHS R15 GM134454NIGMS NIH HHS R35 GM128595
Abstract
Metallo-β-lactamases (MBLs) are a growing clinical threat because they inactivate nearly all β-lactam-containing antibiotics, and there are no clinically available inhibitors. A significant number of variants have already emerged for each MBL subfamily. To understand the evolution of imipenemase (IMP) genes (
Indexed as
beta-LactamasesCarbapenemsAnti-Bacterial AgentsEscherichia coliMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsbeta-lactamasecarbapenemasecarbapenemsimipenemaseIMPS262GV67F
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.